Novo Nordisk shares dropped after slashing full-year sales guidance, primarily due to weakening sales of its blockbuster GLP-1 drugs, Ozempic…
Novo Nordisk shares dropped after slashing full-year sales guidance, primarily due to weakening sales of its blockbuster GLP-1 drugs, Ozempic…